Breast cancer:: from estrogen to androgen receptor

被引:120
|
作者
Andò, S
De Amicis, F
Rago, V
Carpino, A
Maggiolini, M
Panno, ML
Lanzino, M
机构
[1] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy
[2] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, CS, Italy
关键词
breast cancer; estrogen; androgen;
D O I
10.1016/S0303-7207(02)00105-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and postmenopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E-2. DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E-2 (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E-2 presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E-2 proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E-2 action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574 --> Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E-2 signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E-2. This seems to be related to the inhibitory effects of the over-expressed AR on E-2 genomic action. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [1] Post-menopausal breast cancer: from estrogen to androgen receptor
    Majumder, Avisek
    Singh, Mahavir
    Tyagi, Suresh C.
    ONCOTARGET, 2017, 8 (60) : 102739 - 102758
  • [2] Androgen Receptors in Estrogen Receptor Positive Breast Cancer
    Richer, Jennifer K.
    D'Amato, Nicholas
    Spoelstra, Nicole
    Cox, Marc B.
    Elias, Anthony
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [3] Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer
    Agrawal, Anil
    Ziolkowski, Piotr
    Grzebieniak, Zygmunt
    Jelen, Michal
    Bobinski, Piotr
    Agrawal, Siddarth
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (08) : 550 - 555
  • [4] Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
    Basile, Debora
    Cinausero, Marika
    Iacono, Donatella
    Pelizzari, Giacomo
    Bonotto, Marta
    Vitale, Maria Grazia
    Gerratana, Lorenzo
    Puglisi, Fabio
    CANCER TREATMENT REVIEWS, 2017, 61 : 15 - 22
  • [5] Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
    Ni, Min
    Chen, Yiwen
    Lim, Elgene
    Wimberly, Hallie
    Bailey, Shannon T.
    Imai, Yuuki
    Rimm, David L.
    Liu, X. Shirley
    Brown, Myles
    CANCER CELL, 2011, 20 (01) : 119 - 131
  • [6] A review of estrogen receptor/androgen receptor genomics in male breast cancer
    Severson, Tesa M.
    Zwart, Wilbert
    ENDOCRINE-RELATED CANCER, 2017, 24 (03) : R27 - R34
  • [7] The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer
    Lim, Elgene
    Hickey, Theresa A.
    Selth, Luke A.
    Chia, Kee Ming
    Milioli, Heloisa H.
    Roden, Daniel
    Laven-Law, Geraldine
    Jindal, Shalini
    Hui, Mun
    Ebrahimie, Esmaeil
    Birrell, Stephen N.
    Stelloo, Suzan
    Caldon, C. Elizabeth
    Finlay-Schultz, Jessica
    Abdel-Fatah, Tarek M.
    Ellis, Ian O.
    Zwart, Willbert
    Palmieri, Carlo
    Sartorius, Carol A.
    Swarbrick, Alex
    Carroll, Jason S.
    Tilley, Wayne D.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Targeting androgen receptor in estrogen receptor-negative breast cancer
    Ni, Min
    Chen, Yiwen
    Bailey, Shannon T.
    Imai, Yuuki
    Liu, X. Shirley
    Brown, Myles
    CANCER RESEARCH, 2011, 71
  • [9] The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
    Theresa E. Hickey
    Luke A. Selth
    Kee Ming Chia
    Geraldine Laven-Law
    Heloisa H. Milioli
    Daniel Roden
    Shalini Jindal
    Mun Hui
    Jessica Finlay-Schultz
    Esmaeil Ebrahimie
    Stephen N. Birrell
    Suzan Stelloo
    Richard Iggo
    Sarah Alexandrou
    C. Elizabeth Caldon
    Tarek M. Abdel-Fatah
    Ian O. Ellis
    Wilbert Zwart
    Carlo Palmieri
    Carol A. Sartorius
    Alex Swarbrick
    Elgene Lim
    Jason S. Carroll
    Wayne D. Tilley
    Nature Medicine, 2021, 27 : 310 - 320
  • [10] The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
    Hickey, Theresa E.
    Selth, Luke A.
    Chia, Kee Ming
    Laven-Law, Geraldine
    Milioli, Heloisa H.
    Roden, Daniel
    Jindal, Shalini
    Hui, Mun
    Finlay-Schultz, Jessica
    Ebrahimie, Esmaeil
    Birrell, Stephen N.
    Stelloo, Suzan
    Iggo, Richard
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Abdel-Fatah, Tarek M.
    Ellis, Ian O.
    Zwart, Wilbert
    Palmieri, Carlo
    Sartorius, Carol A.
    Swarbrick, Alex
    Lim, Elgene
    Carroll, Jason S.
    Tilley, Wayne D.
    NATURE MEDICINE, 2021, 27 (02) : 310 - +